Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | AJ1-11095 |
Synonyms | |
Therapy Description |
AJ1-11095 is a non-covalent JAK2 inhibitor that binds active and inactive JAK2 and prevents heterodimerization with JAK1 and TYK2, which may induce apoptosis and inhibit proliferation in tumor cells (Blood (2024) 144 (Supplement 1): 3147.1, NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
AJ1-11095 | AJ1 11095 | JAK2 Inhibitor 19 | AJ1-11095 is a non-covalent JAK2 inhibitor that binds active and inactive JAK2 and prevents heterodimerization with JAK1 and TYK2, which may induce apoptosis and inhibit proliferation in tumor cells (Blood (2024) 144 (Supplement 1): 3147.1, NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06343805 | Phase I | AJ1-11095 | A Phase 1 Study of AJ1-11095 in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i) | Recruiting | USA | 0 |